INNATE PHARMA SA (IPHA): Price and Financial Metrics

INNATE PHARMA SA (IPHA): $2.88

0.50 (+21.01%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

Add IPHA to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#103 of 471

in industry

IPHA Price/Volume Stats

Current price $2.88 52-week high $3.57
Prev. close $2.38 52-week low $1.81
Day low $2.38 Volume 57,874
Day high $2.90 Avg. volume 10,475
50-day MA $2.58 Dividend yield N/A
200-day MA $2.72 Market Cap 232.88M

IPHA Stock Price Chart Interactive Chart >


INNATE PHARMA SA (IPHA) Company Bio


Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells.


IPHA Latest News Stream


Event/Time News Detail
Loading, please wait...

IPHA Latest Social Stream


Loading social stream, please wait...

View Full IPHA Social Stream

Latest IPHA News From Around the Web

Below are the latest news stories about INNATE PHARMA SA that investors may wish to consider to help them evaluate IPHA as an investment opportunity.

Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi

MARSEILLE, France, December 19, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate’s ANKET® (Antibody-based NK Cell Engager Therapeutics) platform pursuant to the terms of the research collaboration and license agreement signed in December 2022. Following a research collaboration period, Sanofi will be responsible

Yahoo | December 19, 2023

Innate Pharma Announces Leadership Change

MARSEILLE, France, December 18, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that Mondher Mahjoubi has resigned from his position as Chief Executive Officer (CEO) and Chairman of the Executive Board of the Company, effective as of January 2024, to pursue a senior level opportunity at a large pharmaceutical company.

Yahoo | December 18, 2023

Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023

MARSEILLE, France, December 11, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that the updated efficacy and safety results from an open-label, first-in-human, Phase 1/2 dose-escalation study of SAR443579 / IPH6101, an investigational CD123 targeting NKp46/CD16-based Natural Killer Cell Engager (NKCE) from a joint research collaboration between Innate Pharma and Sanofi were shared in a poster presentation at the American So

Yahoo | December 11, 2023

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

MARSEILLE, France, December 10, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced positive final results from the Phase 2 TELLOMAK study in Sézary Syndrome (SS). The results were presented at the ASH 2023 Annual Meeting, in San Diego, California.

Yahoo | December 10, 2023

Innate Pharma to Host Virtual KOL Event on Lacutamab

MARSEILLE, France, November 27, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that it will host a virtual KOL (Key Opinion Leader) event on lacutamab, a first-in-class anti-KIR3DL2 antibody currently in development for cutaneous T-cell lymphoma (CTCL) and peripheral T cell lymphoma (PTCL), on Tuesday, December 12, 2023, at 7:00AM PST (4:00PM CET).

Yahoo | November 27, 2023

Read More 'IPHA' Stories Here

IPHA Price Returns

1-mo 7.17%
3-mo 2.86%
6-mo 13.83%
1-year 2.49%
3-year -33.64%
5-year N/A
YTD 2.86%
2023 -24.93%
2022 -18.20%
2021 11.49%
2020 -36.49%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!